Moderna (NASDAQ:MRNA) Shares Up 3% - What's Next?

Key Points

• Moderna shares rose 3% to about $214.17 amid optimism over its cancer-vaccine pipeline, particularly the Merck partnership’s Phase 3 melanoma results showing reduced recurrence and distant metastasis.
• Investors are now looking for upcoming financial results to confirm the company’s revenue outlook, cost controls, and cash position, while some analysts caution that the stock’s rally may already reflect much of the vaccine’s potential.
• William Blair downgraded Moderna to Market Perform on valuation concerns, and the analyst consensus remains Hold with a $107.10 price target—well below the current share price.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) traded up 3% during mid-day trading on Wednesday. The stock traded as high as $218.16 and last traded at $214.17. 11,910,226 shares changed hands during mid-day trading, a decline of 6% from the average daily volume of 12,682,081 shares. The stock had previously closed at $207.97.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: CEO Stéphane Bancel told The Wall Street Journal that the melanoma vaccine’s results could improve with longer follow-up and argued that Moderna’s technology and manufacturing expertise would be difficult for competitors to replicate. He also expressed confidence that the platform could support cancer vaccines beyond melanoma. Moderna CEO cancer vaccine comments
• Positive Sentiment: Detailed Phase 3 data presented at ESMO and accepted for publication in the New England Journal of Medicine provided additional validation for Moderna and Merck’s individualized mRNA vaccine combined with KEYTRUDA. The treatment significantly reduced melanoma recurrence and distant metastasis, supporting the long-term value of the oncology pipeline. Moderna Phase 3 melanoma vaccine validation
• Neutral Sentiment: Investor attention is shifting toward the company’s upcoming financial results. Analysts and investors want evidence that Moderna’s revenue outlook, cost controls, and cash position can support the elevated expectations created by the recent oncology rally. Moderna ESMO and Q3 outlook
• Negative Sentiment: William Blair downgraded MRNA from Outperform to Market Perform, citing valuation after the stock’s substantial rally. The downgrade reinforces concerns that much of the cancer-vaccine opportunity may already be reflected in the share price, even though the firm did not necessarily dispute the scientific potential. William Blair valuation downgrade
• Negative Sentiment: The Phase 3 melanoma results showed meaningful benefits but reportedly fell short of the market’s highest expectations, creating uncertainty over the vaccine’s ultimate commercial value and contributing to recent volatility. Merck and Moderna cancer vaccine results

Analysts Set New Price Targets

MRNA has been the subject of a number of recent research reports. Berenberg Bank raised their price target on shares of Moderna from $45.00 to $100.00 and gave the stock a "hold" rating in a research report on Friday, September 11th. Loop Capital set a $135.00 price target on shares of Moderna in a report on Wednesday, August 19th. CLSA raised Moderna to an "outperform" rating in a research report on Friday, August 28th. Piper Sandler reissued an "overweight" rating and issued a $230.00 price objective (up from $167.00) on shares of Moderna in a report on Monday. Finally, Morgan Stanley upped their target price on Moderna from $89.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 7th. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $107.10.

Moderna Stock Up 3.0%

The firm has a market capitalization of $85.50 billion, a price-to-earnings ratio of -26.80 and a beta of 1.09. The business has a 50 day simple moving average of $176.73 and a 200-day simple moving average of $83.73. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.13) EPS. On average, equities analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

Insiders Place Their Bets

In related news, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company's stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last 90 days. Corporate insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently bought and sold shares of the business. Physician Wealth Advisors Inc. increased its holdings in Moderna by 8.3% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company's stock valued at $171,000 after purchasing an additional 68 shares in the last quarter. Fortitude Family Office LLC grew its position in shares of Moderna by 53.1% in the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company's stock worth $43,000 after acquiring an additional 77 shares in the last quarter. TD Waterhouse Canada Inc. increased its stake in Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company's stock valued at $246,000 after purchasing an additional 85 shares during the last quarter. SteelPeak Wealth LLC raised its stake in Moderna by 3.9% during the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company's stock worth $654,000 after acquiring an additional 127 shares during the period. Finally, Western Pacific Wealth Management LP acquired a new stake in shares of Moderna during the 3rd quarter worth approximately $29,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.